We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Type Linked to Risk of COVID-19 Infection Severity

By LabMedica International staff writers
Posted on 04 Jan 2021
Identification of risk factors for contracting and developing serious illness following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount interest. More...
Development of COVID-19 is associated with age, sex, and comorbidities, such as cardiovascular diseases, although severe disease is not limited to these risk groups.

Blood group A and B glycosyltransferases also affect glycosylation in a large number of cell types, including epithelial cells in the respiratory tract and shed viral particles. A, B, and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.

Clinical Immunologists at the Odense University Hospital (Odense, Denmark) and their colleagues analyzed data in a retrospective cohort study, of over 840,000 individuals in Denmark who underwent testing by polymerase chain reaction for SARS-CoV-2 between February 27 and July 30, 2020. Most of those tested (56%) had available ABO and RhD blood group information. The team also used ABO and RhD data of 2,204,742 individuals not tested for SARS-CoV-2 as a reference. This corresponded to approximately 38% of the entire Danish population.

The scientists reported that of the 473,654 tested individuals who had a known blood group, 7,422 were positive for SARS-CoV-2 and 466,232 were negative. The positive and negative groups had similar proportions of men (32.9% versus 32%) and similar median ages (52 years versus 50 years). Among patients with SARS-CoV-2, considerably fewer (38.4%) had blood type O than other tested blood types. When excluding blood type O, they observed no significant differences among patients with blood types A, B and AB. They also observed no difference in the RhD group between positive cases and the reference population. The investigators reported relative risk (RR) for contracting SARS-CoV-2 of 0.87 for blood type O, 1.09 for blood type A, 1.06 for blood type B and 1.15 for blood type AB.

Torben Barington, MD, a Professor of Medicine and the senior author of the study, said, “ABO blood groups are increasingly recognized to influence susceptibility to certain viruses, including SARS-CoV-1 and norovirus. A, B and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.” The study was originally published on October 14, 2020 in the journal Blood Advances.

Related Links:
Odense University Hospital


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.